Track Roche Holding AG's EBIT ($30B) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
Roche Holding AG's ebit stands at $30B as of June 2026. That compares with $29B in the prior-year period — up 0.4% year over year. That is above the Healthcare sector average of $23B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Roche Holding AG reported $30B in EBIT versus $29B a year earlier — a 0.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
Roche Holding AG sits higher the Healthcare benchmark ($23B) with a EBIT of $30B. That is roughly 27.0% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
That compares with $29B in the prior-year period — up 0.4% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how Roche Holding AG's EBIT evolved across reporting periods, while the comparison chart places RHHBF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.